| Ytd | -56.90% | |
| 1y | -15.72% |
| Open | 5.45 | Prev Close | 6.12 | Low | 5.43 | High | 6.55 | Mkt Cap | 12.49M |
| Vol | 567.52K | Avg Vol | 728.17K | EPS | -5.92 | P/E | N/A | Forward P/E | -0.43 |
| Beta | 1.89 | Short Ratio | 0.20 | Inst. Own | 5.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.67 | 200-d Avg | 8.12 | 1yr Est | 4.50 |
QNRX News
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular
US stocks up, Dow gains 100 points, S&P 500 and NASDAQ also rise. Communication services up 1.1%
Shares of Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) are rallying Friday morning following back-to-bac
Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial resul
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark
AFRM: 13% | Affirm Holdings shares are trading higher after the company reported strong Q4 financial
Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raisi
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Comp
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.90) per share which missed the
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton S
ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Comp
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Frida
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Pa
Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Pee
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinica
ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast
The formation follows the recent grant of Orphan Drug Designation to QRX003 by Japan's Ministry
Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commerci
Six pediatric NS patients are currently enrolled in the program, all under 10 years of age, with the
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical
-Designation provides regulatory and development incentives in Japan, including up to 10 years of ma
The IND submission is supported by clinical observations from Quoin's ongoing investigator-led p
-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Ph
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.77) per share which missed the
- Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrom
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNR
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Com
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studi
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studi
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.74) per share which beat the an
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S
ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Com
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinica
— Fast Track Designation facilitates development and expedites regulatory review of therapies addres
